Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Fineline Cube Apr 28, 2026
Company Drug

BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C

Fineline Cube Apr 28, 2026
Company Drug

Sanofi’s VaxigripTetra Expands Influenza Vaccine Access to All Ages in China

Fineline Cube May 17, 2023

French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its tetravalent influenza virus split vaccine,...

Company Drug

AstraZeneca’s Nirsevimab on Track for Priority Review for RSV Prevention in Infants

Fineline Cube May 17, 2023

The Center for Drug Evaluation (CDE) website in China indicates that AstraZeneca’s (AZ, NASDAQ: AZN)...

Company Drug

Antengene Submits Market Approval Filing for Xpovio in Indonesia for Multiple Myeloma and Lymphoma

Fineline Cube May 17, 2023

Antengene Corp., Ltd (HKG: 6996) has announced a market approval filing in Indonesia for its...

Company Drug

TYK Medicines Receives CDE Approval for CDK7 Inhibitor TY-2699a Clinical Study

Fineline Cube May 17, 2023

Shanghai-based TYK Medicines has announced that it has received approval from the Center for Drug...

Company Drug

Transcenta Holdings’ TST002 Shows Positive Phase I Results for Bone Density in China

Fineline Cube May 17, 2023

China-based biotech Transcenta Holdings Ltd (HKG: 6628) has announced encouraging Phase I clinical study results...

Company Drug

BeiGene’s Tislelizumab Secures First Approvals Outside China Mainland in Macau

Fineline Cube May 17, 2023

BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor,...

Company Drug

Yizun Biomedicine’s CNK-UT Cell Therapy Initiates Patient Enrollment for Solid Tumor Trial

Fineline Cube May 17, 2023

Hangzhou-based cell therapy specialist Yizun Biomedicine Co., Ltd has announced the completion of first patient...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting

Fineline Cube May 17, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...

Company Drug

Zelgen Biopharmaceuticals’ ZG0895 Receives FDA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube May 16, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Deals

Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline

Fineline Cube May 16, 2023

Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared...

Company Legal / IP

Philips Agrees to $62 Million Settlement with SEC Over China Marketing Practices

Fineline Cube May 16, 2023

The US Securities and Exchange Commission (SEC) has announced that Dutch device company Philips (BVMF:...

Company Deals

Drug Farm Secures $27 Million in Series C Financing to Advance HBV Treatments

Fineline Cube May 16, 2023

Drug Farm, a Sino-US biotech company specializing in hepatitis B virus (HBV) treatments, oncology, and...

Company Medical Device

Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong

Fineline Cube May 16, 2023

Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful...

Company Deals

BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors

Fineline Cube May 16, 2023

US-based biotech company BiOneCure Therapeutics Inc. has entered into a strategic collaboration with China-based Nanjing...

Company Drug

Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study

Fineline Cube May 16, 2023

China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of...

Company Drug

Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD

Fineline Cube May 16, 2023

Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing...

Company Drug

Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy

Fineline Cube May 16, 2023

Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an...

Company Deals

Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D

Fineline Cube May 16, 2023

Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership...

Company Drug

CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces

Fineline Cube May 16, 2023

The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates...

R&D

COVID-19 Disruptions Lead to Soaring Lab Monkey Prices, Impacting US Drug Development

Fineline Cube May 16, 2023

The COVID-19 pandemic has led to a significant reduction in the export of laboratory monkeys...

Posts pagination

1 … 517 518 519 … 658

Recent updates

  • Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization
  • Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise
  • Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
  • Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design
  • BeBetter Medicine Secures FDA Clearance for BEBT-701 Clinical Study – First-in-Class Dual-Target Therapy for Hypertension and High LDL-C
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Company Drug

Novartis Secures European Commission Approval for Rhapsido (remibrutinib) in Chronic Spontaneous Urticaria – Expanding Global BTK Inhibitor Franchise

Others

Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms

Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.